Cubist Systematic Strategies LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Cubist Systematic Strategies LLC bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 40,349 shares of the company's stock, valued at approximately $2,160,000. Cubist Systematic Strategies LLC owned 0.08% of Janux Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after buying an additional 442 shares in the last quarter. Rhumbline Advisers increased its position in Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after buying an additional 599 shares in the last quarter. Kennedy Capital Management LLC increased its position in Janux Therapeutics by 7.9% during the 4th quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock valued at $681,000 after buying an additional 928 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Janux Therapeutics by 5.8% in the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock worth $926,000 after purchasing an additional 949 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after purchasing an additional 1,095 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded up $1.01 during trading hours on Friday, hitting $24.28. The company's stock had a trading volume of 931,458 shares, compared to its average volume of 868,653. The business has a 50 day moving average price of $28.66 and a two-hundred day moving average price of $40.63. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71. The company has a market cap of $1.44 billion, a PE ratio of -20.75 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other news, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares of the company's stock, valued at $314,582,722.74. This trade represents a 1.10% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. This trade represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

JANX has been the subject of a number of research analyst reports. Scotiabank reduced their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Finally, Wedbush reissued an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Janux Therapeutics has an average rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.